Case 1:22-cv-02229-MKV Document 45-4 Filed 10/04/22 Page 1 of 3
`Case 1:22-cv-02229-MKV Document 45-4 Filed 10/04/22 Page 1of3
`
`
`
`
`
`
`
`
`
`
`EXHIBIT D
`EXHIBIT D
`
`

`

`Case 1:22-cv-02229-MKV Document 45-4 Filed 10/04/22 Page 2 of 3
`
`Pfizer
`
`For Immediate Release
`
`ACUITAS
`
`THERAPEUT CS
`
` January 10, 2022
`
`Pfizer Enters into Agreement with Acuitas Therapeutics for Lipid Nanoparticle
`Delivery System for Use in mRNA Vaccines and Therapeutics
`
`Expands Pfizer’s access to lipid nanoparticle (LNP) formulation technology, offering a strong
`strategic fit with Pfizer’s mRNA strategy
`
`Pfizer gains option to license Acuitas’ LNP technology for up to 10 targets for vaccine or
`therapeutic development
`
`NEW YORK AND VANCOUVER, B.C., January 10, 2022 – Pfizer Inc. (NYSE: PFE) and Acuitas
`Therapeutics, a company focused on developing lipid nanoparticle (LNP) delivery systems to
`enable messenger RNA (mRNA)-based therapeutics, today announced they have entered into a
`Development and Option agreement under which Pfizer will have the option to license, on a non-
`exclusive basis, Acuitas’ LNP technology for up to 10 targets for vaccine or therapeutic
`development.
`
`Acuitas’ clinically-validated LNP technology is used in COMIRNATY®, the Pfizer-BioNTech
`COVID-19 vaccine.
`
`“Our swift delivery of the world’s first mRNA-LNP-based vaccine made clear the promise of
`mRNA-LNP technology,” said Mikael Dolsten, M.D., Ph.D., Chief Scientific Officer and President,
`Worldwide Research, Development and Medical of Pfizer Inc. “We are making significant
`investments to harness the power of the mRNA-LNP technology and deliver potential new
`breakthrough vaccines and therapeutics that address significant unmet needs for patients. This
`agreement expands our LNP capabilities and allows us to explore more projects within our
`existing vaccines area and new therapeutic areas where mRNA-LNP technology holds potential
`for success.”
`
`“Acuitas is extremely proud that its LNP technology contributes to the success of COMIRNATY®
`and is excited to be working with Pfizer to advance new vaccines and therapeutic products,” said
`Dr. Thomas Madden, President & CEO of Acuitas Therapeutics.
`
`About Pfizer: Breakthroughs That Change Patients’ Lives
`At Pfizer, we apply science and our global resources to bring therapies to people that extend and
`significantly improve their lives. We strive to set the standard for quality, safety and value in the
`discovery, development and manufacture of health care products, including innovative medicines
`and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to
`advance wellness, prevention, treatments and cures that challenge the most feared diseases of
`our time. Consistent with our responsibility as one of the world's premier innovative
`biopharmaceutical companies, we collaborate with health care providers, governments and local
`communities to support and expand access to reliable, affordable health care around the world.
`For more than 170 years, we have worked to make a difference for all who rely on us. We routinely
`post information that may be important to investors on our website at www.Pfizer.com. In addition,
`to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer
`News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.
`
`1
`
`https://acuitastx.com/wp-content/uploads/2022/01/Acuitas-Pfizer-Agreement-Release.pdf
`Printed October 2, 2022
`
`

`

`Case 1:22-cv-02229-MKV Document 45-4 Filed 10/04/22 Page 3 of 3
`
`
`About Acuitas Therapeutics
`Founded in February 2009, Vancouver-based Acuitas Therapeutics (www.acuitastx.com) is a
`private biotechnology company that specializes in the development of delivery systems for nucleic
`acid therapeutics based on lipid nanoparticles. The company partners with pharmaceutical and
`biotechnology companies and academic institutes to advance nucleic acid therapeutics into
`clinical trials and to the marketplace. The team works with partners to develop new therapies to
`address unmet clinical needs based on its internationally recognized capabilities in delivery
`technology. Acuitas Therapeutics has agreements in place with several partners to use its
`proprietary lipid nanotechnology in the development of COVID-19 vaccines. These include
`Pfizer/BioNTech for COMIRNATY®, which has received full approval in the U.S. and Canada and
`is authorized for Emergency Use in Europe, the UK and many other countries.
`
`Pfizer Disclosure Notice
`The information contained in this release is as of January 10, 2022. Pfizer assumes no obligation
`to update forward- looking statements contained in this release as the result of new information
`or future events or developments.
`
`This release contains forward-looking information about the potential of mRNA-LNP technology
`and a development and option agreement under which Pfizer will have the option to license, on a
`non-exclusive basis, Acuitas’ LNP technology for up to 10 targets for vaccine or therapeutic
`development, including their potential benefits, that involves substantial risks and uncertainties
`that could cause actual results to differ materially from those expressed or implied by such
`statements. Risks and uncertainties include, among other things, the uncertainties inherent in
`research and development, including the ability to meet anticipated clinical endpoints,
`commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory
`approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and
`further analyses of existing clinical data; the risk that clinical trial data are subject to differing
`interpretations and assessments by regulatory authorities; whether regulatory authorities will be
`satisfied with the design of and results from our clinical studies; whether and when any
`applications may be filed for any drug or vaccine candidates in any jurisdictions; whether and
`when regulatory authorities may approve any potential applications that may be filed for any drug
`or vaccine candidates in any jurisdictions, which will depend on myriad factors, including making
`a determination as to whether the product’s benefits outweigh its known risks and determination
`of the product’s efficacy and, if approved, whether any such drug or vaccine candidates will be
`commercially successful; decisions by regulatory authorities impacting labeling, manufacturing
`processes, safety and/or other matters that could affect the availability or commercial potential of
`any drug or vaccine candidates; whether the agreement between Pfizer and Acuitas will be
`successful; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and
`financial results; and competitive developments.
`
`A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form
`10-K for the fiscal year ended December 31, 2020 and in its subsequent reports on Form 10-Q,
`including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and
`Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of
`which are
`filed with
`the U.S. Securities and Exchange Commission and available
`at www.sec.gov and www.pfizer.com.
`
`
`###
`
`
`
`2
`
`https://acuitastx.com/wp-content/uploads/2022/01/Acuitas-Pfizer-Agreement-Release.pdf
`Printed October 2, 2022
`
`